Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MCA herbal Web site

This article was originally published in The Tan Sheet

Executive Summary

UK Medicines Control Agency launches 1"Herbal safety news" site in late May to provide consumers, practitioners, manufacturers and suppliers with information on safety issues associated with herbal medicines. Online material includes advice on herbal use, safety concerns associated with poor quality of traditional Chinese medicines. Other sections address safety issues for botanicals such as aristolochia, kava, St. John's wort and BotanicLabs' PC-SPES, which was recently recalled due to possible contamination with the Rx drug warfarin (2"The Tan Sheet" May 29, 2002, p. 3)...

You may also be interested in...



NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors

The National Center for Complementary & Alternative Medicine is evaluating the future of multiple PC-SPES studies it is funding following Brea, Calif.-based BotanicLab's recent announcement it is going out of business

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel